DiscoverNewsRamp Science, Exploration and Discovery PodcastPromising Results of CNM-Au8 in MS Patients Presented at ECTRIMS 2025 Congress
Promising Results of CNM-Au8 in MS Patients Presented at ECTRIMS 2025 Congress

Promising Results of CNM-Au8 in MS Patients Presented at ECTRIMS 2025 Congress

Update: 2025-09-25
Share

Description

Clene Inc. showcased encouraging outcomes from the REPAIR-MS trial at ECTRIMS 2025 Congress, demonstrating that CNM-Au8 enhanced brain NAD+/NADH ratios in MS patients, impacting energy capacity. The treatment correlated with changes in brain NAD+ and NADH fractions, influencing disability and cognitive function. CNM-Au8 exhibited good tolerability and potential in slowing MS progression by addressing bioenergetic failure, positioning it as a hopeful therapy under investigation by Clene Inc., a biopharmaceutical company specializing in neurodegenerative diseases.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Promising Results of CNM-Au8 in MS Patients Presented at ECTRIMS 2025 Congress

Promising Results of CNM-Au8 in MS Patients Presented at ECTRIMS 2025 Congress

NewsRamp